⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 17, 2025Open Access

Supplemental Table S4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Funda Meric‐Bernstam Martin Gutierrez Enrique Sanz‐García Diego Villa Jun Zhang Jennifer Friedmann Fengting Yan Mark A. Socinski John Sarantopoulos Luis E. Raez Quincy S. Chu Maxime Chénard-Poirier Manash S. Chatterjee Hong Ren Qi Liu Douglas A. Levine Komal Jhaveri

View Full Paper

Ask AI

Bookmark

Share

Key Points

The results highlight the efficacy of zilovertamab vedotin in treating patients with metastatic solid tumors.
Using RECIST version 1.1, the study provides a detailed investigator assessment of treatment outcomes.
Participants in the study showcased a response to the therapy, suggesting a promising avenue for future treatments.
The findings may support ongoing clinical development of zilovertamab vedotin for difficult-to-treat tumors.

Implication

This phase 2 study assesses efficacy in metastatic solid tumors using RECIST criteria, indicating potential benefits.

Abstract

Supplemental Table S4. Efficacy Results per RECIST Version 1.1 by Investigator Assessment

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Meric‐Bernstam et al. (2025) studied this question.

synapsesocial.com/papers/68d462b631b076d99fa61af7 https://doi.org/10.1158/2767-9764.30146487

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
2Supplemental Table S2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
3Supplemental Table S3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
4Supplemental Table S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
5Table 1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025

More related papers

Supplemental Table S1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
Supplemental Fig S4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
Supplemental Table S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025